ICON8 trial reaffirms standard dosing in ovarian cancer chemo
(European Society for Medical Oncology) European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cancer | Cancer & Oncology | International Medicine & Public Health | Ovarian Cancer | Ovaries | Politics | Women